Xpert® Breast Cancer STRAT4
Standardized breast cancer ESR1/PGR/ERBB2/MKi67 mRNA biomarker assessment in less than two hours
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
GXBCSTRAT4-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
product image
1 Tests
GXFFPE-LYSIS-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support

The Need

Breast cancer biomarker ER/PGR/HER2/Ki-67 results need to be dependable and objective
  • Clinicians need more reliable ER/PGR/HER2/Ki-67 assessment in FFPE tumor tissues.
  • 5% of HER2 IHC results are equivocal based upon guide line recommended classifications.1
  • Resolving HER2 IHC2+ equivocal results with FISH is challenging.1-4
  • Technical and observer variability can lead to approximately 20% inaccurate ER and PGR results.5
  • Ki-67 IHC scores deviate due to a lack of standardization.6
(1)Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor
(2)Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
(3)Starczynski J et al. HER2 Gene Amplification in Breast Cancer. A Rogues' Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations. AM J Clin Pathol. 2012 Apr;137(4):595-605.
(4)Rakha A et al. Updated UK Recommendations for HER2 assessment in breast cancer. Clin Pathol. 2015 Feb;68(2):93-99.
(5)Hammond MEH et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Onc. 2010 Feb 23; 28(16): 2784-2795.
(6)Polley MYC et a.l An International Ki67 Reproducibility Study. J Natl Cancer Ins. 2013 Dec 18;105(24):1897-906.

The Solution

Xpert® Breast Cancer STRAT4 paves the way for a standardized, precise and reliable ER/PGR/HER2/Ki-67 mRNA assessment in less than 2 hours
  • Xpert Breast Cancer STRAT4 delivers semi-quantitative determination of ER/PGR/HER2/Ki-67 mRNA levels in FFPE invasive breast cancer sections
    • CYFIP1* reference gene is used for sample normalization
    • Three controls included in each test
    • Software report allows for objective and easy result interpretation
    • External FFPE controls# available for identifying errors, shifts, trends and operator variabilities
CYFIP1: Cytoplasmic FMR1 interacting protein 1
# For Research Use Only. Not for use in diagnostic procedure. Not reviewed by any regulatory body.

The Impact

Xpert Breast Cancer STRAT4 standardizes reproducible ER/PGR/HER2/Ki-67 assessment
  • Clear and accurate results empower oncologists.
  • Enables flexibility, simplicity and random access for a streamlined workflow 24/7.
  • Easy and fast test implementation.
  • Internal controls meet quality management requirements.
  • Robust test and workflow that doesn't require a PCR laboratory.
Performance
Xpert Breast Cancer STRAT4 results are highly concordant with ER/PGR/Ki-67 IHC and IHC/FISH (HER2)7
Xpert Breast Cancer STRAT4 vs. IHC biomarker assessmentPPANPAOPA
ESR1/ER97.2%95.0%97.5%
PR/PGR89%92.9%89.8%
ERBB2/HER2 (Xpert vs IHC)100%92.4%93.3%
ERBB2/HER2 (Xpert vs FISH)100%92.0%93.3%
ERBB2/HER2 (Xpert vs. IHC+FISH)100%91.2%92.4%
MKi-67/Ki-6788.7%100%90.5%
Positivity detection cut-offs of Xpert Breast Cancer STRAT4 for ER/PGR/HER2 correlate with those in ASCO-CAP, St. Gallen Consensus and ESMO Guidelines.1,5,8,9
(7)Xpert® Breast Cancer STRAT4 Package Insert. Sunnyvale. USA. 2017
(8)Gnant M et al. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care. 2015 Apr;10(2):124-130.
(9)Senkus et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v8-30.# For Research Use Only. Not for use in diagnostic procedures.* CE-IVD. In Vitro Medical Device. Not available in the U.S. Not available in all countries.^ Limited to one per customer.